Fluvirin is a trivalent, sub-unit (purified surface antigen) Influenza virus vaccine indicated for active immunization against Influenza disease caused by Influenza virus subtype A and subtype B contained in the vaccine. It is licensed for use in persons 4 years of age and older. FLUVIRIN has been standardized according to the 2016- 2017 influenza season and contains the currently circulating 3 viruses:
- A/Christchurch/16/2010, NIB-74 (H1N1) (an A/California/7/2009 pdm09-like virus);
- A/Hong Kong/4801/2014, NYMC X-263B (H3N2) (an A/Hong Kong/4801/2014-like virus);
- B/Brisbane/60/2008, wild type (a B/Brisbane/60/2008-like virus).
- Children 4 years through 8 years should receive one or two doses of 0.5 mL each of Fluvirin depending on their previous vaccination history. 2 doses should be administered at least 1 month apart
- 9 years and older should receive one dose of 0.5 mL Fluvirin
Annual revaccination with the current vaccine is recommended because immunity declines during the year after vaccination, and also circulating strains of Influenza virus change from year to year.
For latest IAP updates see revised immunization schedule.
Influenza A vaccine (seasonal)-inactivated
History of severe allergic reactions (e.g., anaphylaxis) to egg proteins, or any component of FLUVIRIN or life-threatening reactions to previous influenza vaccinations.